How did Vertex's revenue and expenses trend in Q4 2024?

Vertex Pharmaceuticals experienced a revenue of $666.78 million and incurred $66.67 million in R&D expenses and $52.73 million in SG&A expenses in Q4 2024: |code|Ticker|Name|Date|Total Revenue (FY)|R&D Expenses (FY)|Net Income (FY)|market_code| |---|---|---|---|---|---|---|---| |VERX|VERX.O|Vertex|2024|6.66776E8|6.6666E7|-5.2729E7|185|